Where OATS sits in hip cartilage treatment

For most patients asking about OATS or mosaicplasty, the first question is practical: is this major surgery, or something less disruptive? The honest answer sits in between — it is a single-stage operation, but it restores rather than replaces the hip joint.

Hip cartilage treatment follows a four-tier pathway. The first tier — symptom management and physiotherapy — addresses pain without touching the underlying damage. The second adds biologic support: injection-based treatments such as PRP or hyaluronic acid that reduce inflammation and support the joint environment. The third tier, cartilage restoration, is where OATS belongs. The fourth tier is joint replacement, reserved for end-stage disease.

OATS (Osteochondral Autograft Transfer System) and mosaicplasty — the same technique using multiple plugs — sit firmly in that restoration tier. They are classified under what is sometimes called the 'Repair' stage of the treatment pathway: appropriate when a focal defect has healthy surrounding cartilage borders and the joint as a whole is worth preserving. Unlike microfracture, which stimulates a surface-level fibrocartilage response, OATS transfers both the cartilage layer and the bone beneath it — addressing the full thickness of the defect in a single procedure.

The technique is well established in the knee. In the hip, the anatomy is more demanding and the evidence base smaller, which is why patient selection and surgical experience both carry greater weight.

Who hip mosaicplasty suits

The typical patient who benefits from hip mosaicplasty is a young, active adult — most commonly under 50 — with a focal defect on the femoral head that has produced mechanical symptoms: catching, locking, or progressive pain that has not settled despite a genuine trial of physiotherapy and conservative management.

Defect size is the most decisive factor

Of all the variables assessed before surgery, lesion size carries the greatest clinical weight. Defects under 2 cm² are reliably addressed with autograft mosaicplasty, and long-term data suggest a THA conversion rate of around 12% in this group. For lesions at or above 2 cm², that figure rises sharply — to approximately 57% in published series — meaning that more than half of patients with larger defects eventually require hip replacement. This is not a reason to avoid consultation; it is precisely the kind of information that shapes a realistic pre-operative conversation about expectations and options, which for larger defects may include allograft rather than autograft transfer.

Underlying causes

The defects most commonly treated with hip mosaicplasty arise from avascular necrosis (AVN), acute trauma such as a femoral head fracture, or femoroacetabular impingement (FAI). Hip dysplasia is a further cause, and when dysplasia co-exists, combining the osteochondral transfer with a simultaneous periacetabular osteotomy (PAO) may improve how long the repair holds.

Risk factors discussed at counselling

Female sex and the presence of concomitant FAI are each associated with a higher rate of eventual hip replacement and are discussed frankly at the pre-operative stage — not as absolute bars to surgery, but as part of shared decision-making about risk and benefit.

Commitment to post-operative rehabilitation is also part of the candidacy picture: structured recovery over several months influences the quality of cartilage restoration, and patients need to be prepared for that investment before surgery is planned.

How the procedure works

Imagine a small area of worn or damaged cartilage on the femoral head as a pothole in a road surface. The repair principle behind mosaicplasty is straightforward: cylindrical cores of healthy cartilage and the bone immediately beneath it are taken from a less-trafficked part of the same joint — or from the non-weight-bearing surface of the ipsilateral knee — and press-fitted into precisely drilled tunnels at the defect site. When several smaller plugs are arranged side by side to fill the area, the mosaic pattern gives the technique its name.

Donor site: where the graft comes from

Two donor options are used in practice. The first is the non-weight-bearing zone of the patient's own inferior femoral head — tissue already inside the operative field. The second is the non-weight-bearing surface of the ipsilateral knee joint. A 2023 meta-analysis of 11 studies found that knee-derived donor plugs were associated with superior functional outcomes, though the overall evidence remains limited to small case series and this signal should be interpreted with caution rather than as a definitive rule. Either donor site carries a degree of morbidity — harvesting tissue from the knee, in particular, warrants an honest pre-operative discussion about the potential for donor-site symptoms.

Two operative approaches

The choice of surgical access depends largely on where the defect sits and how large it is. A minimally invasive direct anterior approach avoids formal hip dislocation and is well suited to smaller lesions on the anterior femoral head. For larger or more posteriorly positioned defects, surgical hip dislocation provides the broader exposure needed to reach the full femoral head surface and is also the route used when allograft tissue is required.

Allograft OATS for advanced AVN

Where post-collapse avascular necrosis has left a defect too large for autograft, a fresh femoral head allograft — sourced from a tissue bank rather than the patient — can be transferred via a vessel-sparing dislocation technique. This is a distinct variant of the procedure, used in a specific clinical scenario, and is not interchangeable with standard autograft mosaicplasty.

Recovery after hip mosaicplasty

Structural cartilage repair quality after OATS is measurably affected by what happens in the weeks and months following the operation. A study comparing rehabilitation approaches found MOCART 2.0 scores of 96.1 in patients who completed a 12-week progressive programme augmented with bone marrow aspirate concentrate (BMAC), compared with 80.2 for a standard 12-week protocol and 71.7 where the programme was shortened to six weeks. Both the duration of rehabilitation and whether it is biologically supported influence how well the transferred cartilage consolidates — the difference between the full and abbreviated protocols is not marginal.

Milestones to expect

Return to weight-bearing typically occurs at around ten weeks post-operatively, with full return to physical activities at approximately ten months. These figures are best documented for allograft AVN cases; autograft mosaicplasty follows a similar graduated progression, with the exact schedule shaped by defect size, surgical approach, and consultant direction.

BMAC as a surgical adjunct

BMAC in this context is used at the time of surgery to support plug integration — it is an adjunct to the operative procedure, not a standalone injection treatment. The functional gains described above come from the combination of a technically sound repair and a full structured recovery, not from the biologic alone.

Lincolnshire Hip provides a structured follow-up pathway after hip cartilage surgery. Patients considering mosaicplasty are assessed for their ability to commit to an extended supervised programme — the evidence is unambiguous that the length and quality of rehabilitation directly shape the structural outcome.

What the evidence shows at 10 years

Ten-year follow-up data from a series of 24 hips give the clearest picture available of what hip mosaicplasty delivers in the longer term. Patients whose hip joint was still intact at a mean of 9.5 years (range 7–14 years) reached a mean modified Harris Hip Score of 87.2 and a mean WOMAC score of 84.1 — both in the good-to-excellent range. A 2023 systematic review and meta-analysis drawing on 11 studies and 70 patients confirmed a mean Harris Hip Score improvement of approximately 32 points post-operatively, and found this gain to be broadly consistent across different patient ages, defect aetiologies, and follow-up durations.

The counterpart to those gains is that roughly 25% of patients in the 10-year series required conversion to total hip arthroplasty, at a mean of around 5.1 years after their original operation. This is a figure that belongs in every pre-operative conversation — not as an indictment of the technique, but as an honest framing of the joint-preservation wager: the majority retain a functional hip at a decade, but a meaningful minority do not. The factors most strongly associated with eventual conversion — defect dimensions, sex, and the presence of FAI — have already been outlined in the candidacy discussion above and should inform the consent process in the same way.

The honest state of the evidence

It would be misleading to present these figures with the same confidence that comparable knee OATS data would support. The mean methodology quality score across meta-analysed studies was 44.32 out of 100 — rated poor — and every included study is a small case series. No randomised controlled trial data exist for hip mosaicplasty, and no published series has followed patients systematically beyond 14 years. The outcome picture after that point is genuinely unknown.

This is not a reason to dismiss the procedure for appropriate patients, but it does mean that clinical decision-making must rest on honest expectations rather than high-certainty projections.

Limitations, evidence gaps, and what to ask at consultation

The gap between how often hip cartilage pathology exists and how often it is formally recognised is striking: MRI studies identify chondral lesions in up to 76% of patients presenting with mechanical hip symptoms, yet osteochondral defects account for only around 2% of formal diagnoses. For patients, this matters practically — the longer a defect goes unrecognised, the less joint tissue remains available to preserve, which is why early specialist imaging can change what options are still on the table.

One area where published evidence has not yet caught up with surgical practice is the role of combining mosaicplasty with concomitant procedures. Labral repair and FAI correction are commonly performed alongside hip cartilage work, but whether doing so materially alters long-term outcomes — and for which patients — remains incompletely defined. Surgeons draw on clinical judgement here rather than on protocol derived from trial data. Similarly, outcomes beyond 14 years have not been captured in any systematic follow-up programme.

These gaps inform what a pre-operative consultation can honestly deliver. Understanding what is established (consistent functional gains, key candidacy factors, approximate THA conversion rate) alongside what is not helps patients ask more targeted questions rather than accepting broad reassurances.

Questions worth raising at a hip preservation consultation

• What is the size and exact location of my defect, and does it fall within the range where mosaicplasty performs reliably?
• Where would donor graft be taken from, and what does that mean for my recovery?
• Which surgical approach is planned, and how does it shape the rehabilitation pathway?
• Would concomitant procedures — such as FAI correction or labral repair — be recommended at the same time, and what is the reasoning?
• If mosaicplasty is not the right fit, what is the next most suitable option within a full hip preservation plan?

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for a personalised hip preservation assessment, with clinics accessible from Sleaford and Grantham.

1. [1] Femoral Head Fracture with Hip Dislocation Treated by Autologous Osteochondral Transfer (Mosaicplasty): A Case Report. (2020). https://doi.org/10.12671/jkfs.2020.33.2.96 https://doi.org/10.12671/jkfs.2020.33.2.96
2. [2] Positive predictors of hip mosaicplasty outcomes: a systematic review and meta-analysis with knee comparison. (2023). https://doi.org/10.21037/aoj-25-10 https://doi.org/10.21037/aoj-25-10
3. [3] Femoral head mosaicplasty by direct anterior approach for an osteochondral impaction without performing surgical hip dislocation. (2021). https://doi.org/10.1051/sicotj/2021014 https://doi.org/10.1051/sicotj/2021014
4. [4] Femoral head osteochondral allograft transplantation with and without simultaneous periacetabular osteotomy: a case series. (2025). https://doi.org/10.1093/jhps/hnaf037 https://doi.org/10.1093/jhps/hnaf037
5. [5] Promising outcomes of hip mosaicplasty by minimally invasive anterior approach using osteochondral autografts from the ipsilateral femoral head. (2019). https://doi.org/10.1007/s00167-019-05442-1 https://doi.org/10.1007/s00167-019-05442-1
6. [6] EP149 Hip mosaicplasty provides good-to-excellent clinical scores at 10 years in patients with small femoral osteochondral lesions. (2025). https://doi.org/10.1093/jhps/hnaf069.277 https://doi.org/10.1093/jhps/hnaf069.277
7. [7] Enhancing Bone–Cartilage Interface Healing in Osteochondral Autograft Transplantation: Effects of BMAC Augmentation and Rehabilitation Protocols. (2025). https://doi.org/10.3390/life15071066 https://doi.org/10.3390/life15071066
8. [8] EP1.64 Femoral Head Osteochondral Allograft Transplantation with Simultaneous Periacetabular Osteotomy for Femoral Head Undercoverage – A Case Series. (2025). https://doi.org/10.1093/jhps/hnaf011.174 https://doi.org/10.1093/jhps/hnaf011.174
9. [9] Surgical Treatment of Juvenile Hip Chondroblastoma Using Mosaicplasty: A Case Report. (2026). https://doi.org/10.3390/life16050752 https://doi.org/10.3390/life16050752